Sermorelin Glycine: What the Combination Is and How It Works

Sermorelin glycine is a compounded peptide preparation that combines sermorelin acetate, a synthetic growth hormone–releasing hormone (GHRH) analog, with glycine, a simple amino acid. In most of these products glycine is not a second active drug — it serves as a stabilizer, buffer, or bulking agent that keeps the peptide stable after reconstitution. The growth hormone–releasing activity comes from sermorelin, not from the glycine.

Labels often render the combination as sermorelin/glycine, which can make it sound like two active ingredients working together. That wording usually describes a formulation choice rather than a two-drug stack.

What Sermorelin/Glycine Usually Means on a Label

Compounded peptides appear in a few different formats, and where glycine sits on the label tells you which one you are looking at.

• Lyophilized powder: glycine is added as a bulking agent so the freeze-dried cake forms properly and dissolves cleanly.
• Pre-mixed solution: glycine acts as a buffer and tonicity agent, holding pH and osmolarity in a range that protects the peptide.
• Excipient listing: glycine shows up in the inactive ingredients, often alongside mannitol, sodium chloride, or a preservative.

Some vials list the contents as glycine sermorelin acetate, which puts the inactive component first and can confuse buyers who assume glycine is doing part of the work. In every case, the active peptide is sermorelin.

Why Glycine Is Added to Sermorelin

Sermorelin is a 29-amino-acid peptide, and peptides are fragile. They can lose potency through aggregation, adsorption to container walls, or pH drift once they are in solution. Glycine helps with all three problems.

• Buffering: glycine solutions resist pH swings that would degrade the peptide.
• Stability: it reduces aggregation and helps the peptide survive reconstitution and storage.
• Bulk and tonicity: it gives the lyophilized powder structure and keeps the final solution close to physiological osmolarity.

Glycine is a common excipient in FDA-approved peptide and protein injectables, so its presence in a sermorelin vial is not unusual. Glycine is included in sermorelin products to protect the peptide, not to add a second hormonal signal.

Does Glycine Raise Growth Hormone on Its Own?

Glycine is also sold as a standalone supplement, usually marketed for sleep and relaxation rather than for growth hormone. Small studies have looked at glycine and subjective sleep quality, and the results are modest at best.

Glycine does not directly stimulate the pituitary to release growth hormone the way sermorelin does. Sermorelin binds GHRH receptors in the pituitary and triggers a pulse of growth hormone release; glycine has no comparable receptor-level action on that pathway.

Some people take oral glycine at night while running a sermorelin protocol, which is where the two ideas often get blended in forum discussions. There is no solid evidence that adding oral glycine increases sermorelin's effect.

Sermorelin, Glycine, and the Combination Compared

A sermorelin/glycine vial is a delivery format for sermorelin. Glycine does not change the dose of the active peptide or its mechanism of action.

How Sermorelin Glycine Compares With Other Peptides

People researching sermorelin usually end up comparing it with the other growth hormone–related peptides sold by the same vendors. Half-life and receptor target are the two differences that matter most.

The comparison of sermorelin vs aod 9604 comes up often because both are marketed for body composition, even though they work through different mechanisms. In the same way, cjc-1295 vs sermorelin usually comes down to half-life and how smooth the resulting growth hormone elevation is.

Clinics sometimes describe a sermorelin and cjc-1295 stack, but combining two GHRH analogs is largely redundant because they hit the same receptor. A sermorelin cjc-1295 blend is usually just a longer-acting GHRH analog standing in for the shorter one.

Safety, Legality, and Sourcing

Sermorelin glycine is not FDA-approved for human use in the United States, and no large clinical trials establish its long-term safety in healthy adults. Geref, the brand-name sermorelin product approved in the 1990s for diagnostic testing in children, was discontinued in 2008.

In 2020, federal regulators moved to restrict compounding of sermorelin under Section 503A, which is why most sermorelin sold online today is labeled for research use only rather than as a prescription drug. Buying from a research-chemical vendor means no dosing oversight, no sterility guarantee, and no recourse if a vial is mislabeled.

Reported side effects of sermorelin include injection-site reactions, flushing, headache, and dizziness. Because it acts on the pituitary, shifts in cortisol, prolactin, or blood sugar are possible, and the peptide can interact with other medications.

• Talk with a licensed healthcare professional before using any growth hormone–related peptide.
• Ask about baseline and follow-up bloodwork, including IGF-1.
• Ask whether the product was made in a licensed compounding pharmacy and how it was tested for purity.

Anyone with a history of pituitary tumors, cancer, or uncontrolled diabetes should treat these products as off-limits without medical supervision.